Esperion Therapeutics, Inc. (ESPR) — SEC Filings
Esperion Therapeutics, Inc. (ESPR) — 50 SEC filings. Latest: ARS (Apr 16, 2026). Includes 21 8-K, 13 SC 13G/A, 6 10-Q.
View Esperion Therapeutics, Inc. on SEC EDGAR
Overview
Esperion Therapeutics, Inc. (ESPR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Esperion Therapeutics, Inc. reported a significant increase in total revenues for the nine months ended September 30, 2025, reaching $234.689 million, a decrease from $263.201 million in the prior year. Product sales, net, surged to $115.846 million for the nine months ended September 30, 2025, up f
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Esperion Therapeutics, Inc. is neutral.
Filing Type Overview
Esperion Therapeutics, Inc. (ESPR) has filed 1 ARS, 1 DEFA14A, 6 10-Q, 21 8-K, 1 8-K/A, 2 DEF 14A, 2 10-K, 13 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of ESPR's 25 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $234.689M |
| Net Income | -$84.513M |
| EPS | -$0.43 |
| Debt-to-Equity | N/A |
| Cash Position | $92.447M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Joelle L. Lipton
- Ms. Pamela J. Maragliano-Muniz
- Mr. Koenig
- Mr. Timothy Mayleben
- Joqin V. Diaz
Industry Context
Esperion operates in the highly competitive cardiovascular drug market, specifically focusing on lipid-lowering therapies. The market is characterized by established players, generic competition, and ongoing innovation in novel mechanisms of action. Key trends include the increasing prevalence of cardiovascular disease and a growing demand for effective and safe treatment options.
Top Tags
corporate-governance (6) · amendment (5) · 10-Q (4) · pharmaceuticals (4) · 8-k (4) · institutional-ownership (4) · material-definitive-agreement (3) · Cardiovascular Disease (2) · Net Loss (2) · sec-filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenues | $234.689M | decreased from $263.201M for the nine months ended September 30, 2024 |
| Product sales, net | $115.846M | increased 37.6% from $84.164M for the nine months ended September 30, 2024 |
| Collaboration revenue | $118.843M | decreased from $179.037M for the nine months ended September 30, 2024 |
| Net loss | $84.513M | widened from $30.427M for the nine months ended September 30, 2024 |
| Cost of goods sold | $101.370M | increased 135.9% from $42.970M for the nine months ended September 30, 2024 |
| Cash and cash equivalents | $92.447M | decreased from $144.761M at December 31, 2024 |
| Total operating expenses | $259.649M | increased from $204.379M for the nine months ended September 30, 2024 |
| Net loss per common share - basic and diluted | $0.43 | increased from $0.17 for the nine months ended September 30, 2024 |
| Common Stock Shares Outstanding | 205,430,219 | as of September 30, 2025 |
| Total stockholders' deficit | $451.361M | increased from $388.722M at December 31, 2024 |
| SEC File Number | 001-35986 | Esperion's SEC filing identifier |
| IRS Employer Identification No. | 26-1870780 | Esperion's tax identification number |
| Product sales, net (Q2 2025) | $40.274M | Increased 42.3% from $28.302M in Q2 2024 |
| Collaboration revenue (6 months ended June 30, 2025) | $72.193M | Decreased from $158.511M in the prior year |
| Total Revenues (6 months ended June 30, 2025) | $147.380M | Decreased from $211.569M in the prior year |
Forward-Looking Statements
- {"claim":"Esperion Therapeutics, Inc. stock may experience increased investor confidence due to the significant institutional ownership reported by Wasatch Advisors LP.","entity":"Esperion Therapeutics, Inc.","targetDate":"Within the next 3-6 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Esperion Therapeutics, Inc. (ESPR)?
Esperion Therapeutics, Inc. has 50 recent SEC filings from Jan 2024 to Apr 2026, including 21 8-K, 13 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ESPR filings?
Across 50 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 46 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Esperion Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Esperion Therapeutics, Inc. (ESPR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Esperion Therapeutics, Inc.?
Key financial highlights from Esperion Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ESPR?
The investment thesis for ESPR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Esperion Therapeutics, Inc.?
Key executives identified across Esperion Therapeutics, Inc.'s filings include Dr. Joelle L. Lipton, Ms. Pamela J. Maragliano-Muniz, Mr. Koenig, Mr. Timothy Mayleben, Joqin V. Diaz.
What are the main risk factors for Esperion Therapeutics, Inc. stock?
Of ESPR's 25 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Esperion Therapeutics, Inc.?
Recent forward-looking statements from Esperion Therapeutics, Inc. include guidance on {"claim":"Esperion Therapeutics, Inc. stock may experience increased investor confidence due to the significant institut.